Nymox Pharmaceutical (NYMX) Reports on Symposium and Panel Discussion on NX-1207 at American Urological Association Annual Meeting  
5/6/2013 9:10:32 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HASBROUCK HEIGHTS, N.J., May 6, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation on NX-1207 drug studies at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Diego, CA between 3:00 and 4:00 pm PDT on Sunday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH) and featured expert panel discussions on the new therapy. The Company is pleased to report that the pivotal U.S. Phase 3 trials of NX-1207 for BPH, NX02-0017 and NX02-0018, have now completed enrollment.

Help employers find you! Check out all the jobs and post your resume.